FDA clears Teleflex’s ARROW FlexBlock continuous peripheral nerve block catheter

Teleflex Incorporated (NYSE:TFX) today announced the ARROW FlexBlock continuous peripheral nerve block catheter has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).    

The ARROW FlexBlock continuous peripheral nerve block catheter is intended for clinicians who use ultrasound-guidance when placing continuous peripheral nerve block catheters. The echogenic, coil-reinforced FlexBlock catheter body is constructed of polyurethane, and the unique catheter design offers a combination of ultrasound visibility, flexibility, and excellent kink resistance. The FlexBlock catheter's tip design is intended to provide clinicians with a predictable spread of anesthetic.

"Teleflex is pleased to be adding the ARROW FlexBlock catheter to our market-leading line of ARROW^® StimuCath^® continuous peripheral nerve block catheters," said Cary Vance, President, Teleflex Anesthesia and Respiratory. "These products, in addition to the StimuQuik^® ECHO peripheral nerve block needles, SureBlock^® spinal trays, and the recently 510(k) cleared FlexTip Plus^® Multi-Port epidural catheters, give Teleflex a clinically differentiated regional anesthesia product portfolio, designed to meet the needs of anesthesiologists in the field of regional anesthesia and acute pain management."